Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells

被引:58
作者
Zhang, Haijun [2 ,3 ]
Liu, Gang [2 ]
Dziubinski, Michele [2 ]
Yang, Zengquan [2 ]
Ethier, Stephen P. [2 ]
Wu, Guojun [1 ,2 ]
机构
[1] Wayne State Univ, Dept Pathol, Karmanos Canc Inst, HWCRC, Detroit, MI 48201 USA
[2] Karmanos Canc Inst, Breast Canc Program, Detroit, MI USA
[3] SE Univ, Sch Med, Genet Res Ctr, Nanjing 210009, Jiangsu, Peoples R China
关键词
PIK3CA; breast cancer; somatic mutation;
D O I
10.1007/s10549-007-9847-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
More than 20 different PIK3CA gene mutations were identified in breast cancer with different frequencies. Whether these breast cancer associated mutations have similar biological effects is largely unknown. In this study, we established a novel cell model using the lentivirus system to express 10 different PIK3CA genes (wild type and mutant) based on the human mammary epithelial cell MCF10A. We found that nine different PIK3CA mutants harbor different abilities to promote cell proliferation and EGF independent growth. In addition, most PIK3CA mutants (except for the wild type PIK3CA, the Q60K and the K111N mutants) had the ability to change the morphogenesis of the MCF10A cell in 3D Matrigel assay. Moreover, different PIK3CA mutants have different abilities to promote colony formation and cell invasion. We further observed that most of the PIK3CA mutants could activate p-AKT and p-p70-S6K in the absence of EGF stimulation. Finally, LY294002, a PI3K inhibitor, can effectively inhibit cell growth in cell lines with different PIK3CAs. Taken together, our results support the notion that different PIK3CA mutations differentially contribute to breast cancer transformation, and exploration of the therapeutic application of these mutations will benefit breast cancer patients with the PIK3CA mutations.
引用
收藏
页码:217 / 227
页数:11
相关论文
共 39 条
  • [1] Arboleda MJ, 2003, CANCER RES, V63, P196
  • [2] The PIK3CA gene is mutated with high frequency in human breast cancers
    Bachman, KE
    Argani, P
    Samuels, Y
    Silliman, N
    Ptak, J
    Szabo, S
    Konishi, H
    Karakas, B
    Blair, BG
    Lin, C
    Peters, BA
    Velculescu, VE
    Park, BH
    [J]. CANCER BIOLOGY & THERAPY, 2004, 3 (08) : 772 - 775
  • [3] Cancer-specific mutations in PIK3CA are oncogenic in vivo
    Bader, AG
    Kang, SY
    Vogt, PK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) : 1475 - 1479
  • [4] Oncogenic PI3K deregulates transcription and translation
    Bader, AG
    Kang, SY
    Zhao, L
    Vogt, PK
    [J]. NATURE REVIEWS CANCER, 2005, 5 (12) : 921 - 929
  • [5] Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
    Bianco, R
    Shin, I
    Ritter, CA
    Yakes, FM
    Basso, A
    Rosen, N
    Tsurutani, J
    Dennis, PA
    Mills, GB
    Arteaga, CL
    [J]. ONCOGENE, 2003, 22 (18) : 2812 - 2822
  • [6] Mutation of the PIK3CA gene in ovarian and breast cancer
    Campbell, IG
    Russell, SE
    Choong, DYH
    Montgomery, KG
    Ciavarella, ML
    Hooi, CSF
    Cristiano, BE
    Pearson, RB
    Phillips, WA
    [J]. CANCER RESEARCH, 2004, 64 (21) : 7678 - 7681
  • [7] The phosphoinositide 3-kinase pathway
    Cantley, LC
    [J]. SCIENCE, 2002, 296 (5573) : 1655 - 1657
  • [8] Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner
    Debnath, J
    Walker, SJ
    Brugge, JS
    [J]. JOURNAL OF CELL BIOLOGY, 2003, 163 (02) : 315 - 326
  • [9] Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
    Debnath, J
    Muthuswamy, SK
    Brugge, JS
    [J]. METHODS, 2003, 30 (03) : 256 - 268
  • [10] The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis
    Eceles, SA
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2001, 6 (04) : 393 - 406